UCB Published P-III Studies (BE MOBILE 1 & 2) Results of Bimekizumab for Axial Spondyloarthritis in the Annals of the Rheumatic Diseases
- The 24wk. results from the P-III studies (BE MOBILE 1 & 2) evaluating the efficacy & safety of bimekizumab vs PBO in adult patients with axSpA incl. active nr-axSpA & AS
- Both trials met their 1EPs & 2EPs @16wk., the therapy showed an improvement in the nr-axSpA & AS and patients continued to increase to 24wk. who achieved ASAS40 response treated with bimekizumab at baseline. Additionally, the ASAS40 responses in patients who switched from PBO to bimekizumab @16wk. reached comparable levels @24wk. as those seen in bimekizumab-randomized patients
- The safety profile was consistent with prior reported studies with no new safety signals. Bimekizumab is a humanized monoclonal IgG1 Ab inhibiting interleukin 17A & interleukin 17F
Ref: UCB | Image: UCB
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.